SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: keokalani'nui who wrote (2599)1/17/2001 8:16:24 PM
From: keokalani'nui  Respond to of 52153
 
The current Doxorubicin (known to cause cardiotoxicity) P2 trial uses troponin as a biomarker for drug-induced cardiotoxicty. I'm sure troponin will increasingly become used for this reason, as more centers and hospitals are able to perform the test. The FDA has held hearings on whether to require it to support preclinical studies.

Wilder